Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

被引：57

作者：

Brownlow, N. ^{[1
]}

Mol, C. ^{[2
]}

Hayford, C. ^{[3
]}

Ghaem-Maghami, S. ^{[1
]}

Dibb, N. J. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England

[2] Takeda San Diego Inc, San Diego, CA USA

[3] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England

来源：

LEUKEMIA | 2009年 / 23卷 / 03期

基金：

英国生物技术与生命科学研究理事会;

关键词：

SRC/ABL KINASE INHIBITOR; C-FMS; IMATINIB; ACTIVATION; BMS-354825; CSF-1; RESISTANCE; DOMAIN;

D O I：

10.1038/leu.2008.237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：590 / 594

页数：6

共 25 条

[1]

Allavena P., 2007, Crit Rev Oncol Hematol

[2] Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].

Berman, E ;

Nicolaides, M ;

Maki, RG ;

Fleisher, M ;

Chanel, S ;

Scheu, K ;

Wilson, BA ;

Heller, G ;

Sauter, NP .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013

[3] Dasatinib suppresses in vitro natural killer cell cytotoxicity [J].

Blake, Stephen J. ;

Lyons, A. Bruce ;

Fraser, Cara K. ;

Hayball, John D. ;

Hughes, Timothy R. .

BLOOD, 2008, 111 (08) :4415-4416

[4] Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580 [J].

Conway, JG ;

McDonald, B ;

Parham, J ;

Keith, B ;

Rusnak, DW ;

Shaw, E ;

Jansen, M ;

Lin, PY ;

Payne, A ;

Crosby, RM ;

Johnson, JH ;

Frick, L ;

Lin, MHJ ;

Depee, S ;

Tadepalli, S ;

Votta, B ;

James, I ;

Fuller, K ;

Chambers, TJ ;

Kull, FC ;

Chamberlain, SD ;

Hutchins, JT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (44) :16078-16083

[5] Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib [J].

Dewar, AL ;

Cambarerí, AC ;

Zannettino, ACW ;

Miller, BL ;

Doherty, KV ;

Hughes, TP ;

Lyons, AB .

BLOOD, 2005, 105 (08) :3127-3132

[6] Opinion - Switching on kinases: oncogenic activation of BRAF and the PDGFR family [J].

Dibb, NJ ;

Dilworth, SM ;

Mol, CD .

NATURE REVIEWS CANCER, 2004, 4 (09) :718-727

[7] A small molecule-kinase interaction map for clinical kinase inhibitors [J].

Fabian, MA ;

Biggs, WH ;

Treiber, DK ;

Atteridge, CE ;

Azimioara, MD ;

Benedetti, MG ;

Carter, TA ;

Ciceri, P ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Galvin, M ;

Gerlach, JL ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Insko, MA ;

Lai, AG ;

Lélias, JM ;

Mehta, SA ;

Milanov, ZV ;

Velasco, AM ;

Wodicka, LM ;

Patel, HK ;

Zarrinkar, PP ;

Lockhart, DJ .

NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336

[8]

FITTER S, 2007, BLOOD

[9] A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations [J].

Irvine, Katharine M. ;

Burns, Christopher J. ;

Wilks, Andrew F. ;

Su, Stephen ;

Hume, David A. ;

Sweet, Matthew J. .

FASEB JOURNAL, 2006, 20 (11) :1921-+

[10] M-CSF mediates TNF-induced inflammatory osteolysis [J].

Kitaura, H ;

Zhou, P ;

Kim, HJ ;

Novack, DV ;

Ross, FP ;

Teitelbaum, SL .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3418-3427

← 1 2 3 →